Loading...

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

PURPOSE: Targeting the prostacyclin pathway is an effective treatment option for pulmonary arterial hypertension (PAH). Patients with PAH have a deficiency of prostacyclin and prostacyclin synthase. Selexipag is an orally available and selective prostacyclin receptor (IP receptor) agonist. Selexipag...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Am J Cardiovasc Drugs
Main Authors: Kaufmann, Priska, Okubo, Kaori, Bruderer, Shirin, Mant, Tim, Yamada, Tetsuhiro, Dingemanse, Jasper, Mukai, Hideya
Format: Artigo
Sprog:Inglês
Udgivet: Springer International Publishing 2015
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4452035/
https://ncbi.nlm.nih.gov/pubmed/25850750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40256-015-0117-4
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!